Ohio Medicine Shoppe receives compounding accreditation
NEW PHILADELPHIA, Ohio The Medicine Shoppe Pharmacy in New Philadelphia, Ohio, has been awarded the Pharmacy Compounding Accreditation Board Seal of Accreditation.
The PCAB Seal of Accreditation recognizes pharmacies that practice the highest standards of compounding and pharmacy services, and have demonstrated a commitment to quality in compounding—the customization of medication to meet an individual patient’s medical needs.
“Receiving the PCAB Accreditation is a monumental moment for our pharmacy,” said Bradley White, New Philadelphia Medicine Shoppe franchisee and pharmacist. ”In the 12 years of serving the New Philadelphia community, we have always maintained the highest of standards in our pharmacy services and are pleased our commitment is being recognized by such a prominent organization as the PCAB. This accomplishment is a result of our entire pharmacy staff’s dedication and hard work.”
The New Philadelphia Medicine Shoppe pharmacy is the second pharmacy in Ohio and the first Medicine Shoppe pharmacy to receive the recognition.
Amgen cuts fewer jobs in R.I. than predicted
WEST GREENWICH, R.I. Despite last month?s reports that drug maker Amgen would lay off 450 employees from its Rhode Island staff, the number is proving to be lower, according to the Associated Press.
Instead, according to reports, Amgen cut 300 employees, after realizing that it needed more workers to help manufacture Enbrel, an arthritis drug.
Amgen has roughly 1,600 workers in Rhode Island. It plans to close one of its manufacturing plants by the end of the year.
The company plans to lay off 1,500 employees across the country as part of a major cost-cutting plan.
Edwards suggests new drug ads wait for two years
LACONIA, N.H. Presidential hopeful John Edwards said Sunday he had outlined a plan to regulate prescription drug companies and their advertising. Edwards suggested that drug makers wait two years to begin advertising their new products to consumers since the cost of advertising has escalated to nearly $4 billion over the past decade.
The two-year delay would prevent television ads from driving consumers to drugs that haven’t been proven safe, said Edwards, who also would require drug companies to get Food and Drug Administration approval before launching major ad campaigns.
“I think two years makes sense. I think it gives enough time for a drug not just to have been tested in clinical trials but to be out among the public, to see what kind of adverse reactions there have been,’’ he told reporters afterward.
Edwards’ plan also includes augmented penalties for companies that violate truth-in-advertising laws, and would require companies to disclose more information about a drug’s side effects and effectiveness compared to placebos and less expensive alternative drugs.
The Democratic hopeful said this idea would ensure that “salesmanship is not trumping the facts, so people learn what the real risks are associated with these drugs,” Edwards said.